Bach Kieu-Tram, Lui Forshing
California Northstate University College of Medicine
CA Northstate Uni, College of Med
Tenecteplase (TNK) is a single-bolus recombinant fibrinolytic agent used to manage intravascular clots. The drug is in the tissue plasminogen activator (tPA) class of medications. FDA-approved indications include acute ST-elevation myocardial infarction (STEMI). Tenecteplase is the thrombolytic agent of choice for acute myocardial infarction. Tenecteplase is becoming more widely used as a thrombolytic agent despite its off-label use in acute ischemic strokes largely because of its efficacy when compared with the FDA-approved alteplase. This activity explores the indications, contraindications, activity, adverse event profile, toxicities, and monitoring of tenecteplase to assist the interprofessional team in caring for patients who need thrombolytic therapy.
替奈普酶（TNK）是一种用于治疗血管内血栓的单剂量重组纤溶药物。该药物属于组织纤溶酶原激活剂（tPA）类药物。美国食品药品监督管理局（FDA）批准的适应症包括急性ST段抬高型心肌梗死（STEMI）。替奈普酶是急性心肌梗死的首选溶栓药物。尽管替奈普酶在急性缺血性卒中的使用属于超适应症用药，但由于与FDA批准的阿替普酶相比具有疗效优势，它正越来越广泛地用作溶栓药物。本活动探讨替奈普酶的适应症、禁忌症、作用、不良事件谱、毒性以及监测，以协助跨专业团队护理需要溶栓治疗的患者。
